Varda launches W-7 to test crystallizing a new class of cancer drugs in orbit

Varda Space Industries launched its W-7 vehicle into orbit on 20 October, its third launch this month and fourth of 2026, the company announced. The W-7 payload will expose an active pharmaceutical ingredient to microgravity as it crystallizes, testing whether orbit-grown crystals can improve solubility for PROTACs, a class of next-generation cancer medicines that tag harmful proteins for destruction by the cell's own waste-disposal machinery. PROTAC molecules are large and dissolve poorly in biological fluids, one of the leading reasons drug candidates fail; in the absence of gravity-driven convection and sedimentation, molecules can form crystal structures that are impossible on Earth, including significantly more soluble forms, the company says. The crystals will return to Earth for analysis, and a meaningful improvement could open a path toward clinical development for a class of compounds that remains difficult to formulate. The launch follows Varda's $250 million raise at a $1.6 billion valuation in September.

DTT summary based on Varda Space Industries press release via PR Newswire's report. The full article is on the publisher's site.